ILC1-like cells can independently cause alopecia areata by affecting hair follicles.
Hair loss from immunosuppressive drugs in transplant patients can affect well-being and treatment adherence, so personalized management is important.
39 citations
,
June 2023 in “Advanced Materials” Microneedles offer a promising, painless, and efficient way to deliver vaccines and therapies directly to the skin.
3 citations
,
July 2022 in “European Journal of Dermatology” Brodalumab is more effective than ustekinumab for treating psoriasis.
38 citations
,
September 2004 in “Journal of Autoimmunity” Alopecia areata patients have more activated T cells in their blood, which may help in developing treatments.
6 citations
,
August 2013 in “Joint Bone Spine” Tocilizumab treatment was associated with significant hair regrowth in one patient and temporary hair loss followed by regrowth in another.
1 citations
,
July 2019 in “Clinical Rheumatology” Leflunomide is more likely to help treat alopecia areata than cause it.
1 citations
,
November 2016 in “Saengmyeong gwahag hoeji/Saengmyeong gwahak hoeji” New treatments for the autoimmune hair loss condition alopecia areata may include JAK inhibitors and other immunomodulators.
2 citations
,
September 2022 in “Frontiers in Immunology” T-regulatory cells are important for skin health and can affect hair growth and reduce skin inflammation.
October 2025 in “Science Advances” IFN-γ production by CD4 T cells is crucial for causing alopecia areata.
May 2024 in “International journal of medicine and psychology.” Age-related immune changes significantly affect disease development in other systems.
April 2018 in “Journal of Investigative Dermatology” Both Th1 and Th2 immune responses are increased in alopecia areata, with Th2 response more strongly linked to how severe the disease is.
May 2026 in “Case Reports in Dermatology” Switching immunosuppressants can improve hair regrowth and well-being in transplant patients experiencing hair loss.
17 citations
,
December 1997 in “Transplantation” Tacrolimus can cause hair loss in kidney transplant patients.
4 citations
,
August 2024 in “Journal of Clinical Medicine” COVID-19 mRNA vaccines may increase the risk of flare-ups in certain inflammatory diseases.
1 citations
,
April 2018 in “Journal of Investigative Dermatology” Simvastatin helps hair regrowth in autoimmune alopecia by directly affecting T cells.
8 citations
,
August 2016 in “Journal of the European Academy of Dermatology and Venereology” Oral tacrolimus helped a rheumatoid arthritis patient regrow hair lost due to alopecia areata.
November 2023 in “Journal of Investigative Dermatology” Highly active but fewer CD14+CD16- monocytes are found in Alopecia Areata patients, regardless of severity.
2 citations
,
May 2023 in “The Journal of Immunology” NXC736 significantly reduced hair loss in mice with alopecia areata.
New treatments for alopecia areata, like JAK inhibitors and immunomodulators, are promising.
January 2026 in “Journal of Investigative Dermatology” Special cells can help regrow hair in alopecia areata.
2 citations
,
April 2025 in “Journal of Investigative Dermatology” T cells affect skin cell genes in inflammatory diseases, and therapy can normalize these changes.
9 citations
,
June 2017 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Local inflammation worsens autoimmune skin conditions by increasing antibody buildup.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
September 2025 in “Figshare” Alopecia areata involves complex immune responses, suggesting broader treatments could help.
March 2018 in “Suez Canal University Medical Journal” New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.
August 2016 in “Journal of Investigative Dermatology” Blocking the CCR5 receptor may be a new way to treat hair loss from alopecia areata.
July 2023 in “Clinical and Experimental Dermatology” Combining baricitinib with low-dose corticosteroids significantly improved severe hair loss in eight patients.
July 2024 in “Clinical Cosmetic and Investigational Dermatology” Certain immune cells are linked to non-scarring hair loss, suggesting potential for immune-targeted treatments.
May 2015 in “Journal of The American Academy of Dermatology” Treatment with biologic agents can significantly improve psoriasis symptoms, and blood biomarkers could potentially predict individual patient's response to treatment.